

Ferrate(VI) oxidation of endocrine disruptors and antimicrobials in water

Virender K. Sharma, X. Z. Li, Nigel Graham and Ruey-an Doong

ABSTRACT

Potassium ferrate(VI) (K_2FeO_4) has advantageous properties such as a dual function as an oxidant and disinfectant with a non-toxic byproduct, iron(III), which makes it an environmentally friendly chemical for water treatment. This paper presents an assessment of the potential of ferrate(VI) to oxidize representative endocrine disruptors (EDs) and antimicrobials during water treatment using information about reaction kinetics and products. Selected EDs were bisphenol A (BPA) and 17α -ethynylestradiol (EE2), estrone (E1), 17β -estradiol (E2), and estriol (E3), and sulfonamides and tetracycline were representative pharmaceuticals. The second-order rate constants, k , of the oxidation reactions at neutral pH were in the range from $6.50\text{--}11.8 \times 10^2 \text{ M}^{-1}\text{s}^{-1}$ and $0.79\text{--}15.0 \times 10^2 \text{ M}^{-1}\text{s}^{-1}$ for EDs and sulfonamides, respectively. At a $10 \text{ mgL}^{-1} K_2FeO_4$ dose, half-lives of the oxidation reaction would be in seconds at a neutral pH. The values of k , and the reaction half-lives, varied with pH. Oxidation products from the reaction with BPA and sulfamethoxazole (SMX) at molar ratios of $\sim 5:1$ were found to be relatively less toxic. Overall, ferrate(VI) oxidation could be an effective treatment method for the purification of waters containing these particular EDs and antimicrobials.

Key words | bisphenol, estrogens, ferrate, removal sulfamethoxazole, tetracycline

Virender K. Sharma (corresponding author)
Department of Chemistry, Florida Institute of
Technology, 150 West University Boulevard,
Melbourne, Florida 32901,
USA
Tel.: 321-674-7310
Fax: 321-674-8951
E-mail: vsharma@fit.edu

X. Z. Li
Department of Civil and Structural Engineering,
The Hong Kong Polytechnic University,
Kowloon, Hong Kong,
China

Nigel Graham
Department of Civil and Environmental
Engineering,
Imperial College, London,
UK

Ruey-an Doong
Department of Biomedical Engineering and
Environmental Sciences,
National Tsing Hua University,
Hsinchu 30013,
Taiwan

INTRODUCTION

Endocrine disruptors (EDs) are compounds which mimic natural hormones in the endocrine system thus causing adverse effects on human and wildlife (Lutz & Kloas 1999). Examples of EDs include natural steroid hormones, synthetic hormones, alkylphenols, bisphenol-A, and phthalate plasticizers. In recent years, several studies have found a variety of EDs in surface waters (Snyder *et al.* 2003; Westerhoff *et al.* 2005). In addition to EDs, pharmaceuticals and personal care products (PPCPs) have also been found in the aquatic environment (Ternes *et al.* 2004; Khetan & Collins 2007). Although levels of pharmaceuticals have been determined in the concentration range of ngL^{-1} to μgL^{-1} , mixtures of pharmaceuticals even at ngL^{-1} can inhibit cell proliferation (Gibson *et al.* 2005; Pomati *et al.* 2006). EDs and PPCPs may thus affect the ecology of the environment (Jobling *et al.* 1998; Mills &

Chichester 2005). For example, some EDs have demonstrated mutagenic and carcinogenic effects (Khetan & Collins 2007). Of the several compounds of PPCPs, detection of antibiotics is of concern due to the possibility of increased bacterial resistance (Gould 1999).


In general, drinking water utilities abstract water from various sources such as, ground water, rivers, streams, springs, or lakes in a watershed; small communities generally receive water from aquifers, while large metropolitan areas receive water from surface sources. In most cases source waters require treatment before use in order to meet national quality standards. Human populations may possibly be exposed to EDs and antibiotics through drinking water produced from surface and ground waters contaminated with such compounds in wastewater discharges and urban runoff (Weyer & Riley 2001; Snyder

et al. 2003; Ongerth & Khan 2004). Importantly, the existence of such compounds in treated water indicates that plant treatment processes do not adequately remove these compounds (Ternes *et al.* 2002; Carbala *et al.* 2004; Miao *et al.* 2004). Among the oxidation processes applied in water treatment, chlorine is commonly used as a pre-oxidant and disinfectant. Although chlorine is effective in oxidizing EDs and antibiotics (Deborde *et al.* 2004; Dodd & Huang 2004, 2007; Lee *et al.* 2004; Pinkson & Sedlak 2004), oxidation reactions produce biologically active by-products (Hu *et al.* 2002, 2003). Those who favour the use of chlorine usually cite its ability to react with ammonia and organic nitrogen to produce chloramines (Pinkson & Sedlak 2004), which help to reduce trihalomethanes. However, the reactivity of chloramines with compounds is much slower than that of free chlorine (HOCl/OCl^-), and there are growing concerns about the formation of nitrosamines and other nitrogen-containing byproducts in chloraminated waters.

Alternatively, ozone can be applied, which can effectively oxidize EDs and antibiotics (Huber *et al.* 2003, 2005; Ning *et al.* 2007), however, due to the potential formation of the bromate ion and other organic by-products, ozonation is not always suitable. Chlorine dioxide (ClO_2) is another oxidant used for disinfection, but its use is restricted to high quality water such as treated surface water (Gates 1998). Dosing of ClO_2 must be kept low, for example, in the United States, dosages ranging from 1.0 to 1.4 mgL^{-1} are used mainly for the preoxidation of surface water (Gates 1998). Reduction of ClO_2 produces chlorite ion, which is considered a blood poison (Condie 1986) and higher dosages of ClO_2 ($>1.4 \text{ mgL}^{-1}$) are likely to produce chlorite levels which exceed the USEPA standard of 1 mgL^{-1} .

Ferrate(VI) ($\text{Fe}^{\text{VI}}\text{O}_4^{2-}$) is an emerging water-treatment chemical, which can address the concerns raised by the currently used oxidants (Sharma 2007a). Interestingly, ferrate(VI) does not react with bromide ion; carcinogenic bromate ion would thus not be produced in the treatment of bromide-containing water (Sharma 2007b). Additionally, ferrate(VI) exhibits many advantageous properties, including a higher reactivity and selectivity than traditional oxidant alternatives, and a significant capability as a disinfectant, antifoulant and coagulant (Jiang & Lloyd 2002; Jiang *et al.* 2005; Sharma 2002; Sharma *et al.* 2005b).

The spontaneous decomposition of ferrate(VI) in water forms molecular oxygen (Equation (1)).



Moreover, the by-product of ferrate(VI) is a non-toxic ferric ion, Fe(III). This fact makes ferrate(VI) an “environmentally friendly” oxidant. Additionally, the ferric oxide produced from ferrate(VI) acts as an effective coagulant which is suitable for the removal of metals, non-metals, radionuclides, and humic acids (Sharma 2002; Sharma *et al.* 2005a).

This paper describes the potential of ferrate(VI) to oxidize representative EDs and antibiotics during water and wastewater treatment. Reaction kinetics information for the oxidation of bisphenol (BPA), steroid estrogens, and antibiotics by ferrate(VI) is provided to determine nominal half-lives of the oxidation processes. The current knowledge of the nature of products from the oxidation is summarized.

ENDOCRINE DISRUPTORS

BPA and estrogens

Among the prominent EDs of environmental significance, two synthetic EDs chemicals, bisphenol A (BPA) and 17 α -ethynylestradiol (EE2), and three natural EDs, estrone (E1), 17 β -estradiol (E2), and estriol (E3) were chosen to investigate and quantify their reaction kinetics with ferrate(VI) (Li *et al.* 2005, 2007); all five have a common character in that they are phenolic-type compounds. Details of the experiments have been reported elsewhere (Li *et al.* 2005, 2007) and which involved the use of high purity potassium ferrate prepared by a method based on the oxidation of ferric nitrate with hypochlorite (Li *et al.* 2005). Briefly, the method can be summarized as follows. The reagents HCl and KMnO_4 were slowly reacted in the correct proportion to produce chlorine. The chlorine was subsequently added to pre-chilled KOH solution with stirring for a period of over 2 h. More KOH was then added into this solution and the resulting suspension was cooled. The precipitate of KCl was removed from the suspension by filtration using a filter paper, leaving a concentrated and strongly alkaline solution of potassium hypochlorite. This yellow solution of KClO was then

stirred rapidly while a certain amount of pulverized $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ was added slowly for over 1 h under cooling conditions ($<5^\circ\text{C}$). In these conditions, the Fe(III) ion was readily oxidized to Fe(VI) and the solution became dark purple in color. KOH was then added in small proportions to the Fe(VI) solution and the mixture was stirred for 20 min. The resulting solution was allowed to stand for a further 40 min. The resulting dark purple slurry was filtered with a glass filter, after which the filtrate was discarded, and the precipitate was washed six times with cold aqueous KOH solution. The filtrate from the washings was collected and added to a flask containing chilled saturated KOH solution. The solution was mixed, allowed to stand for 10 min, and then filtered initially with a glass filter, followed by double filtering with filter papers. The precipitate was flushed with n-hexane, n-pentane, methanol, and diethyl ether. The final product, solid potassium ferrate was collected and stored in a vacuum desiccator prior to further use.

The reactions were shown to follow an overall second-order kinetic model (Li *et al.* 2005, 2007) and the rate constants at pH 7.0 and 8.0 at 25°C are given in Table 1. The rates at the two pH values were calculated from the individual rates for the reactions of ferrate(VI) species (monoprotonated, HFeO_4^- and un-protonated,

FeO_4^{2-}) with un-dissociated (ED) and dissociated (ED^-) endocrine disruptor species. The rate constants for the oxidation of BPA and EE2 by ferrate(VI) at pH 8.0 were found to be lower than that at pH 7.0 (Table 1); this was also observed by Lee *et al.* (2005). Interestingly, no significant differences in rate constants for the oxidation of the estrogens E1, E2, and E3 were observed (Table 1) and therefore removal of these estrogens by ferrate(VI) can be carried out at either pH 8.0 or 7.0 without any difference in the effectiveness of the process. The greater degradation performance of BPA and EE2 by ferrate(VI) at the lower pH may be related to the higher oxidizing power of HFeO_4^- than that of FeO_4^{2-} and that the fraction of HFeO_4^- increases with decreasing pH. Overall, the extent of the ferrate(VI) oxidation will vary with the aqueous conditions since pH, in particular, affects the nature of the ferrate(VI) ion (degree of protonation) and the extent of dissociation of the EDs.

Generally, the application of potassium ferrate(VI) can achieve a major removal of selected EDs within seconds (Table 1). The reaction of BPA with ferrate(VI) was studied in detail in order to identify the formation of intermediate reaction products and the BPA degradation pathways. From the analyses carried out by LC/MS-MS and GC/MS-MS, nine specific compounds were

Table 1 | Second-order rate constants for selected EDs and antibiotics in reaction with ferrate(VI) (pH 7.0 and 8.0; 25°C)

Compound	k ($\text{M}^{-1}\text{s}^{-1}$) pH 8.0	$t_{1/2}^*$	k ($\text{M}^{-1}\text{s}^{-1}$) pH 7.0	$t_{1/2}^*$
<i>EDCs</i> [†]				
Bisphenol A (BPA)	4.29×10^2	32.3 s	6.50×10^2	21.2 s
17 α -ethynylestradiol (EE2)	6.88×10^2	21.1 s	8.13×10^2	17.0 s
Estrone (E1)	1.05×10^3	13.1 s	1.01×10^3	13.7 s
β -estradiol (E2)	1.09×10^3	12.6 s	1.09×10^3	12.6 s
Estriol (E3)	1.29×10^3	11.6 s	1.18×10^3	10.9 s
<i>Antimicrobials</i> [‡]				
Sulfisoxazole	$3.52 \pm 0.10 \times 10^2$	39.3 s	$1.50 \pm 0.03 \times 10^3$	9.2 s
Sulfamethazine	$1.11 \pm 0.02 \times 10^2$	125.0 s	$1.05 \pm 0.08 \times 10^3$	13.2 s
Sulfamethizole	$0.38 \pm 0.01 \times 10^2$	365.0 s	$4.09 \pm 0.41 \times 10^2$	33.9 s
Sulfadimethoxine	–	–	$0.79 \pm 0.07 \times 10^2$	175.0 s
Sulfamethoxazole	$0.46 \pm 0.02 \times 10^2$	301.0 s	$1.33 \pm 0.08 \times 10^3$	10.4 s


*assuming 10 mgL^{-1} K_2FeO_4 dose.

[†]The rate constants calculated using the values and kinetic Equation (12) given in Li *et al.* (2007).

[‡]Sharma *et al.* (2006a).

identified, including *p*-isopropylphenol, *p*-isopropenylphenol, 4-isopropanolphenol, and dicarboxylic acids (e.g. oxalic acid). Whilst under some conditions (e.g. ferrate: BPA molar ratio ~5:1) BPA can be completely degraded in less than 5 minutes, the degree of organic mineralization

was significantly less than 100%, indicating the presence of reaction products which persist well beyond the disappearance of the BPA (Li *et al.* 2007). A pathway of BPA degradation with ferrate(VI) has been proposed as described by Scheme I.



Scheme I | The possible pathway of BPA degradation with ferrate(VI).

ANTIMICROBIALS


Sulfonamides

The rate-law for the oxidation of sulfonamide (S) by ferrate(VI) were found to be first-order for each reactant and can be written as (Sharma *et al.* 2006a,b):

$$-d[\text{Fe(VI)}]/dt = k[\text{Fe(VI)}]_{\text{tot}}[\text{S}]_{\text{tot}} \quad (2)$$

where k represents the second-order rate constant for the reaction of ferrate(VI) with sulfonamide, $[\text{Fe(VI)}]_{\text{tot}}$ represents the total concentration of Fe(VI) species, and $[\text{S}]_{\text{tot}}$ represents the total concentration of each sulfonamide species. The observed second-order rate constants decreased non-linearly with increasing pH (Sharma *et al.* 2006a). The values of k at pH 7.0 and 8.0 at 25°C are reported in Table 1. If there is excess Fe(VI) concentration ($10 \text{ mgL}^{-1} \text{ K}_2\text{FeO}_4$) relative to the sulfonamides in water, as might be expected in practice, the half-lives of the reactions would be short and in the range from 39.3 to 365 s at pH 8.0 (Table 1). The reaction rates are pH dependent, thus, so are the half-lives of the reactions (Table 1). At pH 7.0 under the same conditions, the half-lives would be very short from 9.2–33.9 s (Table 1). It should also be pointed out that reaction rates are also temperature dependent, giving rise to different activation energies of the reaction (Sharma *et al.* 2006a). Therefore, the reaction half-lives will vary significantly with the aqueous environmental conditions.

The oxidation of sulfamethoxazole (SMX) by ferrate(VI) has been found to follow a molar stoichiometry of 4:1 ($[\text{Fe(VI)}]:[\text{SMX}]$). An evolution of one mole of oxygen per mole of SMX was determined (Equation (3)).




For product analysis of the reaction, 0.750 L of $2.0 \times 10^{-4} \text{ M}$ SMX was oxidized with 0.750 L of 0.001 M Fe(VI) at a pH of 9.0 for 3 hours. The reaction mixture was frozen and lyophilized using a Freeze Dry System/Freezone 4.5 (Labconco); followed by extraction procedures (Sharma *et al.* 2006a). Products of the reaction were determined using thin-layer chromatography (TLC), column chromatography, infrared (IR) spectroscopy, ^1H nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry

(ESI MS) techniques. Three products A, B, and C were determined as given in Scheme II.

Interestingly, the reaction resulted in the oxidation of either the isoxazole moiety or the aniline unit of SMX by ferrate(VI). Thus, product A indicates opening of the isoxazole moiety while the presence of predominantly a nitroso and a nitro group in product C and B, respectively, indicates ferrate(VI) attack at the aniline unit. It is possible that at higher molar ratios of ferrate(VI) to SMX, simultaneous oxidation of both the isoxazole and the aniline units might occur. It is possible that such products carry increased polarity and might have been retained on the column during chromatography. Therefore the three products described in Scheme II may not necessarily represent all the products of ferrate(VI) oxidation, but rather the ones that were isolated and characterized. Importantly, the oxidation of the compound by ferrate(VI), whether by the attack on the aromatic or isoxazole rings, will undoubtedly cause the oxidized product to have a differing biological binding property. It is expected that an oxidation of the amino group and/or an oxidation of the isoxazole ring (which leads to its potential opening/destruction) will change its binding properties sufficiently rendering it less of a mimic for the important *p*-aminobenzoic acid. The latter is necessary in the synthesis of the essential vitamin: folic acid. Thus ferrate(VI) not only removes SMX in water, but also produces by-products which are expected to be less toxic.


Tetracycline

The oxidation of tetracycline by ferrate(VI) has been conducted and a stoichiometry of 1.4:1 (Fe(VI):tetracycline)



Scheme II | Products formed in the oxidation of SMX by ferrate(VI).

was proposed (Equation (4)) (Yang & Doong 2008).



The effect of pH on the degradation of tetracycline showed that the removal efficiency of tetracycline increased with increase in pH (Figure 1). The efficiency was only 35% at pH 7.5, but increased to 53–64% when the pH of solutions were higher than 8.3. The results clearly demonstrate that pH is a critical parameter in controlling the degradation of tetracycline by ferrate(VI).

The degradation of tetracycline by ferrate(VI) was also examined by the electrospray ionization-mass spectrometry (ESI-MS) technique (Yang & Doong 2008). In an experiment 200 μM tetracycline was mixed with 50 μM ferrate(VI) and the spectral analysis of tetracycline before and after the reaction was carried out. An expected abundant peak at m/z 410.0 and a small peak at m/z 427 appeared for tetracycline before mixing with ferrate(VI) (Cherlet et al. 2003). After the reaction, a substantial decrease in peaks at m/z 445 and 410 was observed, clearly showing the degradation of tetracycline by ferrate(VI). Additionally, total organic carbon (TOC) analysis also showed that the TOC decreased from an initial concentration of 17.65 mg-C/L to 15.65 mg-C/L after the reaction. However, it is difficult to identify the possible products from the ESI-MS spectra and TOC analysis from the results obtained in this study. Further experiments are necessary to clarify the mechanisms and reactive pathways of tetracycline by ferrate(VI).




Figure 1 | Degradation of tetracycline by ferrate(VI) at different pH. Experimental conditions: [Ferrate(VI)] = 50 μM ; [Tetracycline] = 200 μM (adapted from Yang & Doong 2008).

CONCLUSIONS

The kinetics of the oxidation of bisphenol (BPA), steroid estrogens, and antibiotics by ferrate(VI) were shown to be first-order with respect to each reactant and the observed second-order rate constant, k , increased with a decrease in pH from 8.0 to 7.0 for BPA and sulfonamide antimicrobials. Oxidation of estrogens, E1, E2, and E3 did not show any pH dependence in this pH range. The destruction of EDs and PCCP by ferrate(VI) can be accomplished in seconds at a dose of 10 mgL^{-1} K_2FeO_4 . When the concentration of ferrate(VI) was in excess compared to BPA and sulfamethoxazole, the products of the oxidation were less toxic. Overall, the results have demonstrated that the application of ferrate(VI) is a potentially effective treatment method for controlling EDs and PCCPs in drinking water and wastewater.

Although ferrate(VI) has shown promise to be capable of oxidizing organic micro-pollutants at low levels, the reactions of ferrate(VI) with a wide range of EDs and PCCPs have yet to be investigated to fully assess the potential of ferrate(VI) to degrade these compounds. The kinetic data on pharmaceuticals are only limited to sulfonamides and ibuprofen; hence, it is important to include other drug molecules. Moreover, the nature of the products formed during the oxidation of EDs and pharmaceuticals by ferrate(VI) remains relatively unknown. Because the products can be toxic during transformation of such compounds, it is imperative to perform product studies on the oxidation by ferrate(VI). Finally, it is important to note that the application of ferrate(VI) offers the additional treatment mechanism of coagulation/solid phase adsorption via its reduced Fe(III) species and thus future studies need to evaluate the overall effect of oxidation and coagulation/adsorption on the removal of the parent compounds and daughter products.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the financial support of the Research Grants Committee of Hong Kong Government (RGC No: PolyU 5170/04E) and Chemistry Endowment, Florida Tech for particular aspects of the work described in this paper. We wish to thank two anonymous reviewers for useful comments on the paper.

REFERENCES

- Carbala, M., Omil, F., Lema, J. M., Llompart, M., Garcia-Jares, C., Rodriguez, I., Gomez, M. & Ternes, T. 2004 Behavior of pharmaceuticals, cosmetics, and hormones in a sewage treatment plant. *Water Res.* **38**, 2918–2926.
- Cherlet, M., Schelkens, M., Croubels, S. & De Becker, P. 2005 Quantitative multi-residue analysis of tetracyclines and their 4-epimers in pig tissues by high-performance liquid chromatography combined with positive-ion electrospray ionization mass spectrometry. *Anal. Chim. Acta* **492**, 199–213.
- Condie, L. W. 1986 Toxicological problems associated with chlorine dioxide. *J. Am. Water Works Assoc.* **78**(6), 73–78.
- Deborde, M., Rabouan, S., Gallard, H. & Legube, B. 2004 Aqueous chlorination kinetics of some endocrine disruptors. *Environ. Sci. Technol.* **38**, 5577–5585.
- Dodd, M. C. & Huang, C.-H. 2004 Transformation of the antibacterial agent sulfamethoxazole in reactions with chlorine: kinetics, mechanisms, and pathways. *Environ. Sci. Technol.* **38**, 5607–5615.
- Dodd, M. C. & Huang, C.-H. 2007 Aqueous chlorination of the antibacterial agent trimethoprim: reaction kinetics and pathways. *Water Res.* **41**, 647–655.
- Gates, D. 1998 *The Chlorine Dioxide Handbook*. American Water Works Association, Denver, Colorado, USA.
- Gibson, R., Smith, M. D., Spary, C. J., Tyler, C. R. & Hill, E. M. 2005 Mixtures of estrogenic contaminants in bile of fish exposed to wastewater treatment works effluents. *Environ. Sci. Technol.* **39**, 2461–2471.
- Gould, I. M. 1999 A review of the role of antibiotic policies in the control of antibiotic resistance. *J. Antimicrob. Chemother.* **43**, 459–465.
- Hu, J.-Y., Aizawa, T. & Ookubo, S. 2002 Products of aqueous chlorination of bisphenol A and their estrogenic activity. *Environ. Sci. Technol.* **36**, 1980–1987.
- Hu, J.-Y., Cheng, S., Aizawa, T., Terao, Y. & Kunikane, S. 2003 Products of aqueous chlorination of 17 β -estradiol and their estrogenic activity. *Environ. Sci. Technol.* **37**, 5665–5670.
- Huber, M. M., Canonica, S., Park, G.-Y. & Gunten, U. V. 2003 Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. *Environ. Sci. Technol.* **37**, 1016–1024.
- Huber, M. M., Goebel, A., Joss, A., Hermann, N., Löffler, D., McArdell, C. S., Ried, A., Siegrist, H., Ternes, T. A. & Gunten, U. V. 2005 Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: a pilot study. *Environ. Sci. Technol.* **39**, 4290–4299.
- Jiang, J.-Q. & Lloyd, B. 2002 Progress in the development and use of ferrate(VI) salt as an oxidant and coagulant for water and wastewater treatment. *Water Res.* **36**, 1397–1408.
- Jiang, J. Q., Yin, Q., Zhou, J. L. & Pearce, P. 2005 Occurrence and treatment trials of endocrine disrupting chemicals (EDCs) in wastewater. *Chemosphere* **61**, 544–550.
- Jobling, S., Nolan, M., Tyler, C. R., Brighty, G. & Sumpter, J. P. 1998 Widespread sexual disruption in wild fish. *Environ. Sci. Technol.* **32**, 2498–2506.
- Khetan, S. K. & Collins, T. J. 2007 Human pharmaceuticals in the aquatic environment: a challenge to green chemistry. *Chem. Rev.* **107**, 2319–2364.
- Lee, B.-C., Kamata, M., Akatsuka, Y., Takeda, M., Ohno, K., Kamei, T. & Magara, Y. 2004 Effects of chlorine on the decrease of estrogenic chemicals. *Water Res.* **38**, 733–739.
- Lee, Y., Yoon, J. & Gunten, U. V. 2005 Kinetics of the oxidation of phenols and phenolic endocrine disruptors during water treatment with ferrate (Fe(VI)). *Environ. Sci. Technol.* **39**, 8978–8984.
- Li, C., Li, X. Z. & Graham, N. 2005 A study of the preparation and reactivity of potassium ferrate. *Chemosphere* **61**, 537–543.
- Li, C., Li, X. Z., Graham, N. & Gao, N. Y. 2007 The aqueous degradation of bisphenol and steroid estrogens by ferrate. *Water Res.* **42**, 109–120.
- Lutz, I. & Kloas, W. 1999 Amphibians as a model to study endocrine disruptors: I. Environmental pollution and estrogen receptor binding. *Sci. Total Environ.* **225**, 49–57.
- Miao, X., Bishay, F., Chen, M. & Metcalfe, C. D. 2004 Occurrence of antimicrobials in the final effluents of wastewater treatment plants in Canada. *Environ. Sci. Technol.* **38**, 3533–3541.
- Mills, L. J. & Chichester, C. 2005 Review of evidence: an endocrine-disrupting chemicals in the aquatic environment impacting fish populations? *Sci. Total Environ.* **343**, 1–34.
- Ning, B., Graham, N., Zhnag, Y., Nakonechny, M. & El-Din, M. G. 2007 The degradation of endocrine-disrupting chemicals by ozone and AOPs—a review. *Ozone Sci. Eng.* **29**, 1–24.
- Ongerth, J. E. & Khan, S. 2004 Drug residuals: how xenobiotics can affect water supply sources. *J. Am. Water Works Assoc.* **96**, 94–101.
- Pinkson, K. E. & Sedlak, D. 2004 Transformation of aromatic ether- and amine-containing pharmaceuticals during chlorine disinfection. *Environ. Sci. Technol.* **38**, 4019–4025.
- Pomati, F., Castiglioni, S., Zuccato, E., Fanelli, R., Vigetti, D., Rossetti, C. & Calamari, D. 2006 Effect of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. *Environ. Sci. Technol.* **40**, 2442–2447.
- Sharma, V. K. 2002 Potassium ferrate(VI): an environmentally friendly oxidant. *Adv. Environ. Res.* **6**, 143–156.
- Sharma, V. K. 2007a A review of disinfection performance of Fe(VI) in water and wastewater. *Water Sci. Technol.* **55**, 225–230.
- Sharma, V. K. 2007b Ferrate studies for disinfection and treatment of drinking water. In: Nikolaou, A., Rizzo, L. & Selcuk, H. (eds) *Advances in Control of Disinfection By-Products in Drinking Water Systems*. Nova Science Publishers, Hauppauge, New York, USA, pp. 1–6.
- Sharma, V. K. & Mishra, S. K. 2006 Ferrate(VI) oxidation of ibuprofen: a kinetic study. *Environ. Chem. Lett.* **3**, 182–185.
- Sharma, V. K., Burnett, C. R., Yngard, R. & Cabelli, D. E. 2005a Iron(VI) and iron(V) oxidation of copper(I) cyanide. *Environ. Sci. Technol.* **39**, 3849–3854.

- Sharma, V. K., Kazama, F., Jiangyong, H. & Ray, A. K. 2005b Ferrates (iron(VI) and iron(V)) as environmentally friendly oxidants and disinfectants. *J. Water Health* **3**, 42–58.
- Sharma, V. K., Mishra, S. K. & Nesnas, N. 2006a Oxidation of sulfonamide antimicrobials by ferrate(VI) [$\text{Fe}^{\text{VI}}\text{O}_4^{2-}$]. *Environ. Sci. Technol.* **40**, 7222–7227.
- Sharma, V. K., Mishra, S. K. & Ray, A. K. 2006b Kinetic assessment of the potassium ferrate(VI) oxidation of antibacterial drug, sulfamethoxazole. *Chemosphere* **62**, 128–134.
- Snyder, S. A., Westerhoff, P., Yoon, Y. & Sedlak, D. L. 2003 Pharmaceuticals, personal care products, and endocrine disruptors in water: implications for water industry. *Environ. Eng. Sci.* **20**, 449–469.
- Ternes, T. A., Meisenheimer, M., Mcdowell, D., Sacher, F., Brauch, H.-J., Haist-Gulde, B., Preuss, G., Wilme, U. & Zulei-Seibert, N. 2002 Removal of pharmaceuticals during drinking water treatment. *Environ. Sci. Technol.* **36**, 3855–3863.
- Ternes, T. A., Joss, A. & Siegrist, H. 2004 Scrutinizing pharmaceuticals and personal care products in wastewater treatment. *Environ. Sci. Technol.* **38**(20), 393A–399A.
- Westerhoff, P., Yoon, Y., Snyder, S. & Wert, E. 2005 Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes. *Environ. Sci. Technol.* **39**(17), 6649–6663.
- Weyer, P. & Riley, D. 2001 *Endocrine Disruptors and Pharmaceuticals in Drinking Water*. AWWA Research Foundation, Denver, Colorado, USA.
- Yang, S. F. & Doong, R.-A. 2008 Preparation of potassium ferrate for the degradation of tetracycline. *ACS symp. Ser.* **985**, 405–419.

First received 17 September 2007; accepted in revised form 21 February 2008